This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
alzheimers-disease
Alzheimer's Disease
Neurodegenerative disease defined by amyloid-β plaques and tau tangles; progressive memory loss and dementia. APOE4 is the major genetic risk factor. Anti-amyloid antibodies (lecanemab, donanemab) slow early-stage progression; symptomatic treatment with cholinesterase inhibitors.
Entry Metadata
| Field | Value |
|---|---|
| ID | alzheimers-disease |
| Name | Alzheimer's Disease |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. · PubMed 27025652
- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. · PubMed 29653606
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. · PubMed 36449413